IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors
Zeposia Adds A Second Oral Advanced Therapy
Executive Summary
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.
You may also be interested in...
As BMS Braces For Major LOEs, It All Comes Down To Execution
As Bristol Myers Squibb works through the Revlimid loss of exclusivity and prepares for the Eliquis and Opdivo LOEs, execution is key as it refills its pipeline with new launches and acquired assets.
Bausch’s Amiselimod Hits Phase II Target, But More Clarity Needed
The company reported positive topline data for the drug in ulcerative colitis, but analysts noted caveats about its earliness as well as lackluster performance to date by others in the S1P class.
First Phase III IBD Trial Reads Out Positive For Janssen’s Tremfya
The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.